Pro Medicus Signs Binding AI Finance and Reseller Deal with Echo IQ
Pro Medicus has inked a binding Heads of Agreement with Echo IQ to finance and resell AI algorithms targeting cardiovascular conditions, aiming to integrate these into its Visage 7 Cardiology platform.
- Binding Heads of Agreement signed with Echo IQ
- Financing facility to support AI algorithm development
- Reseller agreement to offer Echo IQ tech to Visage 7 users
- Definitive agreements expected within 20 business days
- Deal aligns with PME's AI strategy for curated algorithm suite
Strategic Partnership Targets Cardiovascular AI Expansion
Pro Medicus Limited (ASX:PME) has taken a decisive step to bolster its artificial intelligence offerings in cardiology by signing a binding Heads of Agreement with Echo IQ Ltd (ASX:EIQ). The agreement sets the stage for a financing facility and reseller arrangement aimed at accelerating the development and commercialisation of Echo IQ’s AI algorithms, notably those addressing aortic stenosis and heart failure.
This move reflects PME’s broader AI strategy to curate a diverse portfolio of algorithms sourced internally, co-developed with clinical partners, and acquired from third parties. Echo IQ’s technology is slated to be offered to PME’s existing Visage 7 Cardiology customers, potentially enhancing the value proposition of the Visage 7 platform.
Deal Terms and Next Steps
The binding Heads of Agreement requires the parties to finalise definitive legal contracts within 20 business days, after which the transaction may be terminated if no agreement is reached. PME has committed to providing updates once these agreements are executed or if the deal falls through.
While the announcement does not disclose financial details, the arrangement includes a financing component to support Echo IQ’s AI solution development, suggesting PME’s intent to deepen its investment in health imaging AI capabilities. This complements PME’s recent string of substantial contract wins and renewals, including multi-million dollar cloud imaging deals across the US healthcare sector, which have been driving its growth trajectory.
Positioning Visage 7 in a Competitive AI Landscape
Dr Sam Hupert, PME’s CEO, highlighted the strategic rationale: "In addition to providing financial backing, we are looking to offer our Visage 7 Cardiology customers the option of Echo IQ’s technology." This suggests PME is keen to keep Visage 7 at the forefront of cardiology imaging platforms by integrating cutting-edge AI tools that can improve diagnostic accuracy and clinical workflows.
Given the increasing adoption of AI in healthcare imaging and PME’s recent contract wins such as the $16M TidalHealth Cloud Imaging Deal, this partnership could further entrench PME’s competitive position. However, the success of this initiative will hinge on the final terms and the market reception of Echo IQ’s algorithms within PME’s customer base.
Bottom Line?
The Echo IQ deal signals PME’s commitment to expanding AI-driven cardiology solutions, but the outcome depends on finalising agreements and successful integration with Visage 7.
Questions in the middle?
- Will the financing facility lead to accelerated development of Echo IQ’s AI algorithms?
- How will PME integrate third-party AI solutions alongside its own algorithms in Visage 7?
- What commercial impact will the reseller agreement have on PME’s cardiology imaging revenue?
